Soft Tissue Sarcoma Market Report 2026

Soft Tissue Sarcoma Market Overview

• Soft Tissue Sarcoma market size has reached to $3.41 billion in 2025 • Expected to grow to $5.17 billion in 2030 at a compound annual growth rate (CAGR) of 8.7% • Growth Driver: Surge In Cancer Incidence Driving Soft Tissue Sarcoma Market Growth • Market Trend: Product Innovation Driving Advancements In Soft Tissue Sarcoma Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Soft Tissue Sarcoma Market?

Soft tissue sarcoma refers to a disease where cancer cells form in the soft tissues of the body which can be diagnosed through biopsy techniques. It is commonly caused in tissues including blood arteries, muscle, neurons, and fat. The main treatment types of soft tissue sarcoma are targeted therapy, chemotherapy, anti-angiogenesis drugs, radiation therapy, and others. Targeted therapy refers to treatment that specifically targets the genes, proteins, or tissue environment that supports the growth and survival of cancer and prevents cancer cells from proliferating, dividing, and creating new cells. The various routes of administration include oral, parenteral, and others. These are used by various end-users such as hospitals, homecare, specialty centers, and others.

What Is The Soft Tissue Sarcoma Market Growth Forecast?

The soft tissue sarcoma market size is expected to see strong growth in the next few years. It will grow to $5.17 billion in 2030 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period can be attributed to novel drug approvals, immunotherapy expansion, molecular testing growth, personalized treatment demand, oncology infrastructure development. Major trends in the forecast period include growth of targeted therapy use, increased genetic profiling, expansion of combination regimens, rising clinical trial enrollment, multidisciplinary care adoption.

Global Soft Tissue Sarcoma Market Segmentation

1) By Treatment: Targeted Therapy, Chemotherapy, Anti-Angiogenesis Drugs, Radiation Therapy, Other Treatments 2) By Route Of Administration: Oral, Parenteral, Other Route Of Administrations 3) By End-Users: Hospitals, Homecare, Specialty Centers, Other End-Users Subsegments: 1) By Targeted Therapy: Tyrosine Kinase Inhibitors (TKIs), Monoclonal Antibodies, Immunotherapy Agents 2) By Chemotherapy: Doxorubicin, Ifosfamide, Gemcitabine, Other Chemotherapeutic Agents 3) By Anti-Angiogenesis Drugs: Bevacizumab, Pazopanib, Axitinib, Other Anti-Angiogenesis Agents 4) By Radiation Therapy: External Beam Radiation Therapy (EBRT), Brachytherapy 5) By Other Treatments: Surgery, Clinical Trials, Supportive Care

What Is The Driver Of The Soft Tissue Sarcoma Market?

The surge in cancer incidence is expected to propel the growth of the soft tissue sarcoma market going forward. Cancer is a broad category of illnesses that can develop in any organ or tissue in the body when aberrant cells proliferate uncontrollably, cross their usual boundaries, and either spread to other organs or invade neighboring body parts. The rise in cancer incidence increases the need for diagnostic procedures, therapeutic regimens, and supportive care choices to meet the unique requirements of patients with several types of cancer or sarcoma, which boosts the market for soft tissue sarcomas. For instance, in July 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, In 2023, an estimated 165,000 Australians were newly diagnosed with cancer, which equates to over 450 cases each day, and males represented about 55% of these diagnoses. Therefore, the surge in cancer incidence is driving the growth of the soft tissue sarcoma industry.

Key Players In The Global Soft Tissue Sarcoma Market

Major companies operating in the soft tissue sarcoma market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, F. Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, Bristol Myers Squibb, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Merck & Co. Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Dr. Reddy's Laboratories Ltd., Lupin Ltd., Philogen S.p.A., Taiho Pharmaceutical Co.Ltd., Nanobiotix S.A.

Global Soft Tissue Sarcoma Market Trends and Insights

Major companies operating in the soft tissue sarcoma market are concentrating on creating innovative products to strengthen their position in the market. For instance, in November 2023, Mercy, a US-based not-for-profit Catholic healthcare organization, introduced an innovative AI-driven texting program called The Chen Chemotherapy Model to proactively prevent hospitalizations related to chemotherapy. This program utilizes a smart texting platform that sends daily messages to chemotherapy patients seven days a week, excluding weekends and holidays. The texts present a list of symptoms, including diarrhea, pain, fever, fatigue, nausea or vomiting, or no symptoms. Patients can select and rate their symptoms, and based on their responses, the information may be escalated to their healthcare provider. The goal is to identify potential issues early and intervene before symptoms worsen, demonstrating Mercy's commitment to leveraging technology for improved patient care in the field of chemotherapy.

What Are Latest Mergers And Acquisitions In The Soft Tissue Sarcoma Market?

In February 2025, GSK Plc, a UK-based healthcare company, acquired IDRx, Inc., for an undisclosed amount. With this acquisition, GSK aims to strengthen its specialty pharmaceuticals portfolio, accelerate innovation, enhance its pipeline of innovative therapies, and expand its capabilities in targeted drug development. IDRx, Inc., is a US-based biopharmaceutical company specializing in the discovery and development of precision medicines for complex diseases.

Regional Outlook

North America was the largest region in the soft tissue sarcoma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the soft tissue sarcoma market report during the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Soft Tissue Sarcoma Market?

The soft tissue sarcoma includes revenues earned by entities by immunotherapy, hormone therapy, photodynamic therapy, and stem cell transplant. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Soft Tissue Sarcoma Market Report 2026?

The soft tissue sarcoma market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the soft tissue sarcoma industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.